21/10/2026 Ultomiris received US FDA accelerated approval for primary immunoglobulin A nephropathy Ultomiris received US FDA accelerated approval for primary immunoglobulin A nephropathy (Ref) AstraZeneca’s Ultomiris (ravulizumab; C5 complement inhibitor) received US FDA accelerated approval to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. The FDA granted the approval after a Priority Review, based on prespecifie

15/06/2026 SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis Ultomiris granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy XBiotech launched Phase 2 trial evaluating vilamakitug for the treatment of active axial spondyloarthritis Spyre announced Part A results from Phase 2 trial of SPY002 in moderate-to-severe UC SynAct Pharma reported Phase 2b data of resomelagon in Rheumatoid Arthritis (Ref) SynAct Pharma AB

21/04/2026 FDA accepted application for Roche’s Gazyva for the treatment of SLE Cristcot announced FDA acceptance of NDA for ngHCA for treatment of UC of the Rectum AstraZeneca announced Phase 3 results for ravulizumab for IgA Nephropathy FDA accepted application for Roche’s Gazyva for the treatment of SLE ( Ref ) Roche announced that the US FDA had accepted a supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab; anti-CD20) for the treatment o